Bloomberg the Company & Products

Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last $13.19 USD
Change Today +0.1597 / 1.23%
Volume 3.6K
As of 8:10 PM 04/27/15 All times are local (Market data is delayed by at least 15 minutes).

ipsen sa-sponsored adr (IPSEY) Snapshot

Previous Close
Day High
Day Low
52 Week High
01/12/15 - $13.35
52 Week Low
08/22/14 - $10.37
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for IPSEN SA-SPONSORED ADR (IPSEY)

Related News

No related news articles were found.

ipsen sa-sponsored adr (IPSEY) Related Businessweek News

View More BusinessWeek News

ipsen sa-sponsored adr (IPSEY) Details

Ipsen S.A. operates as a pharmaceutical company worldwide. It offers drugs in the areas of uro-oncology, endocrinology, neurology, gastroenterology, cardiovascular, and cognitive disorders. The company’s products include Decapeptyl, a peptide formulation for injection in the treatment of advanced prostate cancer; Hexvix that is used to enhance detection of bladder cancer; and Somatuline and Somatuline Autogel, which are used in the treatment of acromegaly and neuroendocrine tumours. Ipsen S.A. also offers NutropinAq, a liquid formulation used in the treatment of growth failure in children and growth hormone deficiency in adults; Increlex, a formulation used for the long-term treatment of growth failure in children and adolescents with severe primary insulin-like growth factor 1 deficiency; and Dysport, a botulinum neurotoxin type A complex used to treat spasticity of upper limbs following a stroke, as well as the spasticity of other muscles. In addition, it provides Smecta, a natural clay-based drug used in the treatment of chronic and acute diarrhea; Forlax, a drug based on a linear polyethylene glycol polymer used in the treatment of constipation; and Tanakan that is used in the treatment of age-related cognitive disorders. Further, the company offers Nisis and Nisisco oral formulations containing valsartan used in the treatment of hypertension; and Adenuric for the treatment of gout. Additionally, it is developing products in the areas of neurology, endocrinology, and uro-oncology, including BN82451, Tasquinimod, Somatuline Autogel, Dysport, Dysport Next Generation, and Decapeptyl. The company was founded in 1929 and is headquartered in Boulogne-Billancourt, France. Ipsen S.A. is a subsidiary of Mayroy S.A.

4,304 Employees
Last Reported Date: 03/30/15
Founded in 1929

ipsen sa-sponsored adr (IPSEY) Top Compensated Officers

Chairman, Chief Executive Officer and Member ...
Total Annual Compensation: €1.8M
Deputy Chief Executive Officer and Interim Ex...
Total Annual Compensation: €1.4M
Compensation as of Fiscal Year 2014.

ipsen sa-sponsored adr (IPSEY) Key Developments

Ipsen and Hannover Medical School Joint Research Collaboration Agreement to Develop New Therapeutics for Patients

Ipsen and Hannover Medical School announced that they have entered into a joint research collaboration agreement. The objective is to develop new therapeutics for patients with serious neurological, endocrinological or oncological disease. The research program aims at testing recombinant botulinum neurotoxin proteins to affect intracellular molecular pathways with targeted secretion inhibitors (TSIs). Ipsen's proprietary platform of TSI proteins is selectively able to deliver neurotoxin endopeptidase into defined target cells and inhibit pathological secretion from that cell. This technology is based upon the endopeptidase activity found within clostridial (botulinum) neurotoxins, which cleaves SNARE proteins that have a fundamental role in vesicular cell secretion.

Ipsen Signs Multi-Year Research Alliance Agreement with Harvard University

Ipsen announced that it has signed a multi-year research alliance agreement with Harvard University. Designed to stimulate new research projects, the alliance will enable researchers at Ipsen and Harvard to identify and develop collaborative programs in the areas of neuroendocrine tumors, neuromuscular disorders, and platform technologies related to toxins and peptides. The agreement builds upon the success of an existing, three-year program initiated in July 2013: supported by Ipsen, the Harvard laboratory of Dr. Min Dong is engineering novel recombinant botulinum toxin molecules that may improve upon the therapeutic characteristics of existing treatments for neuromuscular tremors and spasms.

Ipsen Announces Inauguration of New R&D Center, Ipsen Bioscience, in Cambridge

Ipsen announced the inauguration of its new R&D center, Ipsen Bioscience, in Cambridge (MA, USA). Ipsen's strategic decision to invest in the Ipsen Bioscience facility in Cambridge is an important element of the company’s open innovation strategy and its goal of broadening its partnerships with the American biotechnology, medical and scientific communities.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
IPSEY:US $13.19 USD +0.1597

IPSEY Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Daiichi Sankyo Co Ltd ¥2,151 JPY +28.50
H Lundbeck A/S kr131.90 DKK -0.20
View Industry Companies

Industry Analysis


Industry Average

Valuation IPSEY Industry Range
Price/Earnings 23.1x
Price/Sales 2.7x
Price/Book 3.3x
Price/Cash Flow 23.4x
TEV/Sales 2.5x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact IPSEN SA-SPONSORED ADR, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at